China Creates Saliva HIV Reagent
This article was originally published in PharmAsia News
China's Beijing Wantai Biological Pharmacy Enterprise launched the country's first domestic saliva HIV/AIDS reagent, capable of testing for the HIV1+2 antibody
You may also be interested in...
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.